Page 49 - Solid Tumors News Today

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the first patient was enrolled in EMERGE-201, a Phase 2 clinical trial evaluating the...

Open-label basket trial will assess the safety and efficacy of Zepzelca in patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 4,040,000 shares, a decline of 15.1% from the February 13th total of 4,760,000 shares. Based on an average daily volume of 854,700 shares, the […]

Tislelizumab is now approved in seven indications in China BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative

08.03.2022 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed coverage for Guardant360 TissueNext ...

Continued clinical progress across pipeline of Bicycle Toxin Conjugates (BTCs) and Bicycle tumor-targeted immune cell agonists (Bicycle TICAs) Cash of $438.7 million at December 31, 2021 expected to

This observational trial was designed to assess the safety and efficacy of bevacizumab plus first-line chemotherapy in a real-world setting in Lebanon.

15.02.2022 - – Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 ... Seite 1

Evaluating the efficacy and safety of neoadjuvant nivolumab in combination with chemotherapy in the treatment this population

03.02.2022 iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development | Chief Medical Officer | Dr. Murray Yule